BOTOX® for the Treatment of Platysma Prominence

Platysma Prominence Clinical Trial

Official title:
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Status Completed

Clinical Trial Summary

To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Platysma Prominence

Clinical Trial Details

NCT number	NCT03915067
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 2
Start date	April 23, 2019
Completion date	April 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05134649` - A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence	Phase 3
Completed	`NCT05773053` - A Study of NT 201 Doses in the Treatment of Platysma Prominence	Phase 2
Completed	`NCT04949399` - A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence	Phase 3
Completed	`NCT04994535` - A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence	Phase 3